Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.
Comparing Amgen (NASDAQ:AMGN) and Axsome Therapeutics (NASDAQ:AXSM) involves evaluating the distinct characteristics of a global pharmaceutical giant and an emerging specialist in central nervous system disorders. Amgen functions as a diversified biotech enterprise, providing products to patients across around 100 countries. Conversely, Axsome Therapeutics specializes in treating conditions such as depression and narcolepsy.
While Amgen's strength lies in its expansive scale and consistent cash generation, Axsome is presently concentrating on the marketing of its newer therapies to ensure long-term profitability. Amgen's research and development activities span across various core areas, including inflammation, rare diseases, and oncology. Its extensive reach allows it to distribute its products in approximately 100 countries; however, the revenue is heavily concentrated among a few key distributors, including McKesson (NYSE:MCK), Cencora (NYSE:COR), and Cardinal Health (NYSE:CAH), who accounted for 77% of Amgen's fiscal 2025 revenue.
This level of customer concentration introduces a degree of risk, a common trait among major biotech stocks.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
